News stories about Shire (NASDAQ:SHPG) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Shire earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.4125395987414 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news headlines that may have effected Accern’s rankings:
- Intraday Movers: Shire plc (SHPG) – MostVolatileStocks (press release) (mostvolatilestocks.com)
- Featured Volatile Stock – Shire plc (NASDAQ: SHPG) – Alpha Beta Stock (alphabetastock.com)
- What Analysts Say? Shire plc (SHPG) stock closes Yesterday with -0.35% – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Shire plc : Elections for the interim dividend in respect of the six months to December 31, 2017 – GlobeNewswire (press release) (globenewswire.com)
- Is the Stock Safe to Invest? – Shire plc (NASDAQ: SHPG) – Alpha Beta Stock (alphabetastock.com)
Shares of SHPG stock traded up $1.67 on Friday, hitting $133.45. The stock had a trading volume of 1,013,797 shares, compared to its average volume of 1,049,163. The firm has a market capitalization of $40,482.99, a price-to-earnings ratio of 9.50, a price-to-earnings-growth ratio of 0.77 and a beta of 1.44. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.97 and a quick ratio of 0.55. Shire has a 52 week low of $123.73 and a 52 week high of $192.15.
Shire (NASDAQ:SHPG) last issued its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 EPS for the quarter, beating analysts’ consensus estimates of $3.86 by $0.12. The company had revenue of $4.14 billion for the quarter. Shire had a return on equity of 14.19% and a net margin of 28.17%. Shire’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same period last year, the business posted $3.37 earnings per share. research analysts expect that Shire will post 15.23 earnings per share for the current fiscal year.
The firm also recently declared a semiannual dividend, which will be paid on Tuesday, April 24th. Stockholders of record on Friday, March 9th will be issued a dividend of $0.8937 per share. This represents a dividend yield of 1.33%. This is a positive change from Shire’s previous semiannual dividend of $0.15. The ex-dividend date of this dividend is Thursday, March 8th. Shire’s dividend payout ratio (DPR) is 7.47%.
A number of equities research analysts have issued reports on the company. BidaskClub cut Shire from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Royal Bank of Canada set a $192.00 target price on Shire and gave the company a “buy” rating in a research note on Monday, February 5th. Bank of America raised their target price on Shire from $236.00 to $237.00 and gave the company a “buy” rating in a research note on Monday, February 5th. Zacks Investment Research upgraded Shire from a “sell” rating to a “hold” rating in a research note on Tuesday, February 6th. Finally, Cantor Fitzgerald set a $222.00 target price on Shire and gave the company a “buy” rating in a research note on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the stock. Shire currently has a consensus rating of “Buy” and an average target price of $204.00.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Shire (SHPG) Stock Price” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://ledgergazette.com/2018/03/18/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-shire-shpg-stock-price.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.